First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): A phase 3, open-label, randomized study

Yuankai K. Shi, L. Wang, B. H. Han, W. Li, P. Yu, Y. P. Liu, C. M. Ding, X. Song, Z. Y. Ma, X. L. Ren, J. F. Feng, H. L. Zhang, G. Y. Chen, X. H. Han, N. Wu, C. Yao, Y. Song, S. C. Zhang, W. Song, X. Q. LiuS. J. Zhao, Y. C. Lin, X. Q. Ye, K. Li, Y. Q. Shu, L. M. Ding, F. L. Tan, Y. Sun

Research output: Contribution to journalArticlepeer-review

169 Scopus citations

Abstract

Background: Icotinib has been previously shown to be non-inferior to gefitinib in non-selected advanced non-small-cell lung cancer patients when given as second- or further-line treatment. In this open-label, randomized, phase 3 CONVINCE trial, we assessed the efficacy and safety of first-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance in lung adenocarcinoma patients with epidermal growth factor receptor (EGFR) mutation. Patients and methods: Eligible participants were adults with stage IIIB/IV lung adenocarcinoma and exon 19/21 EGFR mutations. Participants were randomly allocated (1 : 1) to receive oral icotinib or 3-week cycle of cisplatin plus pemetrexed for up to four cycles; non-progressive patients after four cycles were maintained with pemetrexed until disease progression or intolerable toxicity. The primary end point was progression-free survival (PFS) assessed by independent response evaluation committee. Other end points included overall survival (OS) and safety. Results: Between January 2013 and August 2014, 296 patients were randomized, and 285 patients were treated (148 to icotinib, 137 to chemotherapy). Independent response evaluation committee-assessed PFS was significantly longer in the icotinib group (11.2 versus 7.9 months; hazard ratio, 0.61, 95% confidence interval 0.43-0.87; P = 0.006). No significant difference for OS was observed between treatments in the overall population or in EGFR-mutated subgroups (exon 19 Del/21 L 858R). The most common grade 3 or 4 adverse events (AEs) in the icotinib group were rash (14.8%) and diarrhea (7.4%), compared with nausea (45.9%), vomiting (29.2%), and neutropenia (10.9%) in the chemotherapy group. AEs (79.1% versus 94.2%; P < 0.001) and treatment-related AEs (54.1% versus 90.5%; P < 0.001) were significantly fewer in the icotinib group than in the chemotherapy group. Conclusions: First-line icotinib significantly improves PFS of advanced lung adenocarcinoma patients with EGFR mutation with a tolerable and manageable safety profile. Icotinib should be considered as a first-line treatment for this patient population.

Original languageEnglish
Pages (from-to)2443-2450
Number of pages8
JournalAnnals of Oncology
Volume28
Issue number10
DOIs
StatePublished - Oct 2017

Keywords

  • Cisplatin/pemetrexed plus pemetrexed maintenance
  • EGFR mutation-positive
  • First-line
  • Icotinib
  • NSCLC

Fingerprint

Dive into the research topics of 'First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): A phase 3, open-label, randomized study'. Together they form a unique fingerprint.

Cite this